Indivior, GB00BYZ0C031

Indivior stock heads into the open after a 0.14 percent fall

Published on 09/25/2026 at 08:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 24, 2026, Indivior stock stood at USD 35.86, down 0.14 percent, while trading volume reached 50,261 shares. A rights-related announcement involving Indivior was published today.

Moderne Pharma-Produktionsanlage mit Glasfassade und Industrieanlagen im Tageslicht
Indivior PLC mit ISIN GB00BYZ0C031 betreibt moderne Pharma-Produktionsanlage für innovative Suchtmedizin-Präparate weltweit an Patienten, Illustration mit AI erstellt.

Indivior stock closed at USD 35.86 on Nasdaq on September 24, 2026, down 0.14 percent. The session volume was 50,261 shares, providing the clearest dated market profile before the US open.

September 24, 2026 in numbers

Indivior Pharmaceuticals, Inc. (ISIN GB00BYZ0C031) finished at USD 35.86 on Nasdaq on September 24, 2026. The closing figure was below the previous close of USD 35.91, a decline of 0.05 USD or 0.14 percent.

The same Nasdaq quote reported a market capitalization of USD 4.233 billion as of September 24, 2026. A separate market commentary published by Simply Wall St also cited a last close of USD 35.91 in its September 24, 2026 publication.

Rights announcement today

On September 25, 2026, GlobeNewswire reported that Addex Therapeutics regained full global rights to GABAB positive allosteric modulator assets developed under its research collaboration with Indivior UK Limited.

The announcement said the rights return followed Indivior rationalizing research and development activities and the planned merger of Indivior parent company with Supernus Pharmaceuticals. The statement is a company-related item for the session ahead, but it does not provide a US pre-market price indication.

Disclaimer...

en | GB00BYZ0C031 | INDIVIOR | boerse | 70181807 | bgmi